Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00051909

Enrollment

200

Registered

2003-01-20

Start date

2002-11-30

Completion date

2003-06-30

Last updated

2006-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Keywords

Alzheimer's Disease

Brief summary

Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.

Interventions

DRUGLY451395

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Must have a clinical diagnosis of Alzheimer's Disease * Must be at least 50 years of age * Must fluently read and speak English * Must have a reliable caregiver

Exclusion criteria

* Has serious health problems other than Alzheimer's Disease * Cannot swallow whole pills * Has had a menstrual period in the last two years * Takes insulin for diabetes * Has taken Aricept, Reminyl, or Exelon in the last 5 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026